Fever and infection as a consequence of neutropenia, mainly in acute leukaemia or agranulocytosis, were first described about 100 years ago. 1, 2 Because of its rarity, little attention was devoted to the syndrome until neutropenic fever and infection became a significant clinical problem with the common use of cytostatic therapy for cancer.
It was Bodey et al. 3 who clearly demonstrated the close relationship between the level and the duration of neutropenia and the frequency of infection in patients treated with chemotherapy for acute leukaemia. At that time, bacteraemia complicating severe neutropenia was mainly caused by Gram-negative bacilli, namely Pseudomonas aeruginosa, and was associated with a disastrous 90% mortality rate, 4 in spite of the availability of antibiotics active in vitro.
Two major events played a basic role in the change of the mortality of Gram-negative bacillary infections in neutropenic patients: (i) the wide acceptance of empirical therapy and (ii) the optimal use of antibiotic combinations.
It has been recognized that infection with Gramnegative organisms, especially when P. aeruginosa was involved, was often fulminant in neutropenia and killed more than half of the patients within 48 h of onset. 5 In addition, it became clear that neutropenia minimized many signs and symptoms of infection and that fever was often the only early manifestation of sepsis. 6 Based on these observations, the concept of empirical therapy for fever in neutropenic patients was proposed by Schimpff et al. 7 In the study that launched the concept, a combination (carbenicillin gentamicin) active against P.
aeruginosa and other Gram-negative bacilli was used empirically as soon as neutropenic patients became febrile, without waiting for clinical and/or microbiological evidence of infection. There was a dramatic reduction in the mortality associated with retrospectively documented infection due to P. aeruginosa. Although it was unclear whether the empirical approach or the effective combination played the major role, the concept of empirical therapy was very widely accepted without any further controlled investigation. Of course, the early (empirical) use of antibiotics for fever in neutropenic patients makes the microbiological documentation of infection more difficult. As shown in Table I , summarizing data from trials VIII and IX of the International Antimicrobial Therapy Cooperative Group-European Organization for Research and Treatment of Cancer (IATCG-EORTC) in 1290 cases of febrile neutropenia, microbiological documentation was obtained in about 25% of the febrile patients, usually through positive blood cultures. However, as many as 40% of patients remained without any microbiological and/or clinical documentation of infection. The respective response rates to empirical therapy in these two groups of neutropenic patients were 38% and 57%. 8, 9 The value of synergic antibiotic combinations for the treatment of Gram-negative bacillary bacteraemia in neutropenic patients has been demonstrated by Klastersky et al. 10 in a series of studies, culminating in the IATCG-EORTC clinical comparative trial IV, which showed that a full course of ceftazidime amikacin was superior to a regimen in which amikacin was discontinued early. 11 In that study, the overall mortality rate in patients with acute leukaemia and Gram-negative bacillary bacteraemia who received the optimal therapy was 17% (definite infectious The following aspects of the management of patients with granulocytopenia and fever are reviewed in this article: adaptation of initial antibiotic regimens to the recent changes in the most common causative pathogens (namely a change from Gram-negative bacteria to Grampositive bacteria and fungi); subsequent modifications of the empirically administered treatments; improvement of the host's defence by reducing the duration of neutropenia; and indications for out patient therapy of febrile episodes. 4 Besides providing the benefit of synergy, aminoglycoside-containing combinations have the advantage of not leaving untreated a patient whose pathogen would be resistant to -lactams. In IATCG-EORTC trial I, the combination of carbenicillin gentamicin was superior to carbenicillin cephalothin because infections caused by microorganisms resistant to both -lactams responded poorly; 12 in fact, most patients infected with doubly resistant strains died. In IATCG-EORTC trial III, infections caused by -lactam-resistant and aminoglycosidesensitive organisms did not have an increased mortality compared with those due to fully sensitive pathogens, although their response rate to empirical therapy was significantly lower. 13 These observations suggest that the inclusion of the aminoglycoside into the empirical combination might 'buy time' and allow for antibiotic adjustment according to microbiological documentation. Of course, the more frequent use of an aminoglycoside can lead to greater toxicity and requires the monitoring of blood concentrations. However, the value of synergic aminoglycoside-containing combinations has only been demonstrated in patients with prolonged and severe granulocytopenia and concomitant Gram-negative bacteraemia. These conditions were found in only 75 (3.2%) of 2356 patients included in the last three IATCG-EORTC trials, so empirical aminoglycosides can be discontinued early in all other patients.
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Changing microbiological pattern
During the last decade, Gram-negative bacilli have gradually been replaced by Gram-positive cocci as the cause of microbiologically documented infections complicating febrile neutropenia.
As indicated in Table II , summarizing the blood culture data from seven consecutive IATCG-EORTC trials, Gram-positive microorganisms (mainly Staphylococcus epidermidis and various strains of streptococci) now represent 70% of the bacteraemic isolates. That trend has been observed universally. In addition, new pathogens have emerged in neutropenic patients, but at a slower pace than in AIDS patients, and resistant pathogens have become more common. The resistance is either intrinsic, such as the resistance of Candida krusei to imidazoles, or acquired, as exemplified by recent outbreaks of vancomycin-resistant enterococci in patients treated previously with cephalosporins or vancomycin. Constant epidemio- logical surveillance is thus necessary in patients with compromised defences in order to detect the emergence of rare and/or resistant pathogens. The question of whether the emerging Gram-positive organisms should be fully covered by empirical therapy is still unresolved. Most studies of the introduction of vancomycin in Gram-positive infections [14] [15] [16] used vancomycin or teicoplanin because only these antibiotics are effective against all the potential Gram-positive pathogens. These early studies showed the superiority of vancomycin-containing regimens. However, other authors claim that infections caused by S. epidermidis, which are, at the present time, the only pathogens in neutropenic patients for which vancomycin is necessary, are quite indolent and carry a very low mortality rate; thus, these infections would not require empirical therapy before microbiological documentation. 17 On the other hand, streptococcal infections in neutropenic patients can be associated with a high morbidity and a significant mortality rate (c. 20%); 15, 18 therefore, they should be adequately covered empirically, at least in hospitals where these streptococcal infections in neutropenic patients are common.
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In some centres, the problem of streptococcal infections, namely in bone marrow transplant recipients, has been solved by the pre-emptive use of vancomycin. 19, 20 Excessive use of glycopeptides could lead to the emergence of resistance to vancomycin in other bacterial species, such as staphylococci, so other approaches have been used. These include the administration, as a first-line therapy, of piperacillin-tazobactam, in combination with amikacin. This is very effective against most species of streptococci and provides good cover of most Gramnegative organisms. 9 With such an empirical regimen, S. epidermidis is not covered but, as it causes rather indolent infections, vancomycin or teicoplanin can be added at the time of microbiological documentation. This approach avoids the empirical use of vancomycin or teicoplanin in most patients and might help in keeping the emergence of vancomycin-resistant microorganisms at a lower level.
A flow chart for use in chasing antimicrobial therapy in neutropenic patients is given in the Figure. 
Prophylaxis of infection
Better hospital hygiene, the exclusive administration of cooked food, chemoprophylaxis and the early use of effective antibiotics in neutropenic patients have markedly reduced the incidence of Gram-negative organisms as a cause of infection in neutropenic patients. On the other hand, the common use of intravenous lines and chemotherapy-induced mucositis might have, among other factors, increased the frequency of Gram-positive organisms.
Clearly, these epidemiological changes cannot be explained solely by the use of chemoprophylaxis with quinolones.
When quinolones are used for prevention of infection in neutropenic patients, the rate of Gram-negative bacteraemia is reduced to 1-2%. The prevention of Grampositive infections is more difficult; co-trimoxazole and penicillin have been used and found to be effective. 20, 22, 23 The main problem with chemoprophylaxis is the emergence of resistance; however, since the antibiotics used for chemoprophylaxis in cancer patients are widely used in the community, it is unlikely that their use in neutropenic patients will significantly aggravate the overall situation. Therefore, since chemoprophylaxis with quinolones has to date proved very efficacious in preventing Gram-negative infection during neutropenia, it would appear unwise to deny it to our patients. 24 However, close monitoring for the emergence of resistance is mandatory in the prophylactically treated patients and in their environment. Moreover, further research to develop new agents for the prevention of infection is necessary since past experience with the use of antibiotics has taught us that microbes always end up by finding ways of making our preventive strategies useless.
Prophylaxis of fungal and viral infection is another important issue, but it is largely limited to the patients who undergo an allogeneic bone marrow transplant. Imidazoles (like fluconazole) can effectively prevent candidiasis, both superficial and deep-seated; muco-cutaneous lesions due to herpes simplex can be prevented by acyclovir. 25, 26 The prophylaxis of cytomegalovirus (CMV) and Aspergillus spp. infections is particularly difficult, although active agents against these organisms are available. Aspergillosis has been successfully prevented by the nasal nebulization of amphotericin B, 27 in patients whose upper respiratory passages are colonized by Aspergillus. Preemptive administration of low doses of amphotericin B has been effective in preventing fungal infections in bone marrow transplanted patients receiving high doses of corticosteroids for graft-versus-host disease (G-VHD). 28 High-dose acyclovir and ganciclovir have been used in patients with bone marrow transplantation to prevent CMV infections. In patients with suspected CMV infections, ganciclovir has been used as pre-emptive therapy to be administered to high-risk patients, perhaps those with positive surveillance cultures, who have not yet presented clear-cut clinical signs of infection. 29 One might ask whether chemoprophylaxis of infection in neutropenic patients represents very early therapy? All the agents commonly used for chemoprophylaxis today are systemically absorbed and thus may be considered as effective therapy.
The concept of chemoprophylaxis as a pre-emptive therapy is useful because it unifies the approach to febrile neutropenia as a global therapeutic approach. The population of neutropenic patients is heterogeneous. Therefore very early specific approaches (prophylaxis or pre-emptive therapy) might be useful in some circumstances to minimize morbidity and mortality while, in others, more conservative therapies (empirical or microbiologically oriented therapies) are more appropriate.
Such pre-emptive therapies, as already stated, have been used mainly in patients undergoing bone marrow transplantation and have consisted of penicillin and/or vancomycin to prevent and/or treat early streptococcal infection, 23, 30 low-dose amphotericin B in patients receiving high doses of corticosteroids 28 and ganciclovir when a positive bronchoalveolar lavage for CMV has been documented. 29 Following this concept, quinolone prophylaxis might be viewed as a pre-emptive therapy for Gram-negative bacillary infection aimed at reducing the need for broadspectrum empirical antibiotics to treat febrile episodes. 31 
Endpoints for evaluating therapy of febrile neutropenia
Death is the most straightforward endpoint for evaluating the efficacy of therapy for any potentially lethal condition.
The causes of death in febrile neutropenia are shown in Table III ; it summarizes the experience, at the Institut Bordet, with patients who were enrolled in consecutive IATCG-EORTC studies of empirical therapy. It can be seen that the overall mortality during febrile neutropenia has decreased, in our centre, from 24% to 12% over the last 20 years. Of the patients who died during the episode of febrile neutropenia or immediately after it, during a single hospitalization, infection was responsible for the death in 34% and 39% in our first and second study, respectively; the overall rate of infectious deaths was 3-4%. 32, 33 Bleeding was an important cause of death in the first review, but progression of cancer was more frequently responsible for the fatal outcome during the second period. These observations from our centre are supported by other recent studies. In the recently published IATCG-EORTC study, extensive neoplastic disease was responsible for 32 (50%) of the 64 deaths during or after an episode of febrile neutropenia. 9 As shown in Table IV , recent IATCG-EORTC trials (VII, IX and XI) of empirical management of febrile neutropenia all show 8, 9, 34 that the overall mortality ranges between 5% and 12%, with an infectious mortality rate between 1% and 3%. Clearly, mortality cannot serve as a valid endpoint for the evaluation of empirical therapy: the overall mortality is largely related to factors other than infection, such as bleeding or extensive neoplasia, and the infectious mortality rate itself, including deaths from initial and subsequent infections, is now extremely low.
Most authors, have used the response rate to evaluate the efficacy of empirical therapy. Table IV summarizes the data from three recently published IATCG-EORTC trials, each with a large number of patients, a similar degree of neutropenia, an equal proportion of acute leukaemias and a comparable incidence of bacteraemias. 8, 9, 34 It can be seen that the overall response rates range from 52% to 74%; since the ultimate outcome for most patients is excellentfewer than 10% fatalities-successful changes of antimicrobial therapy must have contributed to this improvement. In the latest IATCG-EORTC study, 34 which compared meropenem monotherapy with ceftazidime amikacin, 38% of the patients had a glycopeptide and 25% had an antifungal agent added after the initial regimen had been considered ineffective. Only the response to the initial empirical regimen is indicative of its intrinsic efficacy and should be the parameter for comparing different regimens. The IATCG-EORTC group considers any modification of the initial regimen as a failure, even if the ultimate outcome is satisfactory; others may call it 'success with modification'. Of course, in non-blinded studies, therapeutic modifications can be biased by the clinical impression of the physician in charge. Future prospective studies should be blinded more often and should adopt appropriate methods to evaluate the modifications made during therapy of febrile neutropenia; at the same time, new endpoints should be sought: time to defervescence, duration of hospitalization and quality of life.
The concept of modifying the initial regimen to secure optimal success, the so-called 'success with modification', has been introduced by Pizzo et al. 35 In this early study, the success of initial empirical therapy was 64% and modifications produced success in another 31%, resulting in an overall success rate of 95%. In a more recent study, from the same institution, comparing ceftazidime with imipenem, the initial response rate was only 39%; however, after modification the overall response rate improved to 100%. 36 Another problem with the response rate, as an endpoint to evaluate empirical therapy, is the heterogeneity of the study population (or groups) in different investigations. This makes it difficult to interpret the results towards a change in practice. As already mentioned, a recent trial 36 that compared ceftazidime with imipenem claimed a 100% response rate with virtually no mortality; however, the mean duration of neutropenia was 8 days, the incidence of bacteraemia was only 12% (two Gram-positive infections for every Gram-negative) and the proportion of leukaemic patients was not stated (44% of leukaemia and lymphoma patients). In the IATCG-EORTC studies (trials VIII, IX and XI) which are summarized in Table IV , the overall success rate (as judged by our criteria) was 53% and the mortality rate was 5-12%. However, in these latter studies there were more patients with leukaemia, severe neutropenia and bacteraemia; it is interesting that of the patients undergoing allogeneic bone marrow transplantation the response rate was still 52% and the mortality 12%.
In another study, patients with leukaemia and bone marrow transplants were compared with patients with lymphoma and solid tumours randomized to receive pipercillin tobramycin or ceftazidime; no difference was observed between the two regimens, but the overall response rate to unmodified therapy was 182/593 (31%) in the patients with leukaemia/transplantation and 62/129 (48%) in the lymphoma/solid tumour group. 37 Future studies might usefully look at more careful selection of study populations and stratification of patients by additional prognostic factors.
The number of variable factors in these studies of empirical therapy of febrile neutropenia probably accounts for the difficulty in demonstrating significant differences between the various regimens.
A benefit of synergic combination therapy has been demonstrated only in leukaemic patients with Gramnegative bacteraemia and severe protracted granulocytopenia. 11 They represent a very small subset of the patients treated for febrile neutropenia. However, recent studies suggest that the initial use of combination therapy leads to fewer modifications of the initial regimen and results in shorter hospital stays. 38 Table V summarizes the response rates in bacteraemic patients from recent studies; 8, 9, 34 the response rate with the regimens employed today is worse for Gram-positive bacteraemia (25-50%) than for Gram-negative bacteraemia (54-70%).
The cumulated data presented here are useful in providing a rough indication of the overall effectiveness of standard regimens in patients whose general characteristics are reasonably well defined; they do not demonstrate the superiority of any particular regimen.
Improvement of the host's mechanisms of defence
The major types of immune deficit that clinicians encounter can be divided into six broad categories: (i) granulocytopenia, (ii) deficiencies of cellular immunity, (iii) impairment of humoral immunity, (iv) obstruction of a normal lumen by tumour/fibrosis, (v) central nervous system dysfunction and (vi) damage to normal anatomical barriers, such as the skin or mucosal surface.
The prevention of infection varies with each type of deficit but four general approaches can be applied to all patients: attempts to improve the patient's immune deficiency, reducing rates of acquisition of potential pathogens, suppressing these organisms already colonizing the patient that are likely to result in later infection, and avoiding procedures that disrupt normal anatomical barriers.
As indicated in Table VI , the various defects of the host's defences are associated with infections by different pathogens with different clinical expressions. However, (70) the potential list of pathogens responsible for infection in cancer patients is certainly much longer than this. The availability of recombinant myeloid colonystimulating factors (G-CSF and GM-CSF) has led to new approaches in chemotherapy-induced neutropenia. Based upon the available data, the following recommendations seem appropriate. These growth factors are probably useful in the setting of bone marrow transplantation for reducing the severity and the duration of granulocytopenia. They might also be useful for patients receiving aggressive therapy likely to cause significant ( 500 granulocytes/mm 3 ) granulocytopenia lasting more than a week. However, recent controlled studies in elderly patients with acute myeloblastic leukaemia failed to demonstrate a significant advantage for either G-CSF or GM-CSF. 39, 40 These factors may also prevent recurrence of sepsis that occurred during a preceding episode of neutropenia and allow the administration of chemotherapy at full doses and without delays caused by persisting neutropenia. 41 As far as cellular immune deficiencies are concerned, there have been some successful attempts to transfer immune cells for specific diseases such as CMV. The results, although promising, are still at an early stage. 42 The use of vaccines is another possible approach, but active vaccination has not been very successful in cancer patients because of the poor antibody response. 43 Revaccination has a special role in bone marrow transplanted patients. 44 Passive transfer of antibody may be useful in some instances, such as the prevention of infections caused by varicella-zoster virus; 45 on the other hand, the infusion of anti-endotoxin antibodies has not been successful in neutropenic patients, 46 nor has the use of CMVspecific intravenous immunoglobulin effectively prevented primary CMV infection and disease after bone marrow transplantation. 47 Correction of humoral immune dysfunction with high doses of non-specific intravenous immunoglobulin replacement has decreased the number of bacterial infections in some studies, 48 but this technique has not been widely accepted, except perhaps for patients having undergone allogeneic bone marrow transplantation. 49 
Fungal infections
A review of recent publications concerning fungal infections in cancer patients clearly confirms that protracted severe granulocytopenia is a major risk factor for the development of such infections. Other risk factors, such as Streptococcus pneumoniae bacteraemia Haemophilus influenzae pneumonia the use of broad-spectrum antibacterial agents, corticosteroids and central venous catheters, as well as the type of cytotoxic chemotherapy, the performance status of the patient and the stage of the underlying disease, also predispose to the development of invasive fungal infections. 50 Fungal infection can be documented initially in 5% of patients with febrile neutropenia; this figure has not changed much over the years. It is obvious that bacterial and fungal sepsis can coexist and that the bacteraemia may mask the (more difficult to document) fungal infection; this later manifests itself as a persisting or recurring fever, after the eradication of bacteraemia by empirically prescribed antibiotics. As neutropenia persists, the risk of further fungal infection increases; many fevers in patients with or after prolonged neutropenia are caused by fungi. 51, 52 As shown in Table VII , these fungal infections represent a significant proportion of further infections which are observed during the course of febrile neutropenia; moreover, the mortality associated with these further fungal infections is much higher than that due to further bacterial infections.
It has been suggested that certain categories of granulocytopenic patients may benefit from antifungal prophylaxis and/or empirical therapy; conversely, there are other neutropenic patients who might benefit only marginally from such strategies. 50 Imidazoles, namely fluconazole, for the prevention of local and systemic infections caused by Candida spp. have been effective in granulocytopenic patients; 53 oral polyenes are also active, but less well tolerated. So far, the development of resistance has not been a major problem, but it is of potential concern, especially if prolonged administration becomes routine.
Empirical therapy with antifungal agents in neutropenic patients who do not respond to broad-spectrum antibiotics has become an accepted practice; 54 it is justified by the frequency of fungal infections in granulocytopenic patients and by the difficulties in making an early specific diagnosis. However, the precise indications for its use are still unresolved; as already mentioned, in recent studies of empirical antibacterial therapy, about 25% of patients are eventually given antifungals. 34 In patients at high risk of developing severe fungal infection, such as those receiving high-dose corticosteroid therapy for GVHD or after allogeneic bone marrow transplantation, the early pre-emptive administration of a low dose of amphotericin B was found to be effective in reducing the development of systemic fungal infection. 28 In terms of choice of therapy, amphotericin B is still the standard approach. This particularly applies to empirical treatment given before the recognition of a specific offending pathogen, when both Candida spp. and Aspergillus spp. need to be covered. When the infection is known to be caused by a sensitive variety of Candida spp., imidazoles might be as effective as amphotericin B; however, this has not been established in neutropenic patients. 55 To what extent liposomal preparations of amphotericin B will provide increased clinical efficacy remains to be proven in controlled trials; nevertheless, it seems clear that the side effects related to amphotericin B can be reduced by the use of the liposomal preparations, allowing the administration of increased dosages. 56 Because severe and prolonged granulocytopenia plays such a major predisposing role for fungal infection, it is possible that the use of bone marrow stimulating factors might prove particularly effective in decreasing the frequency and severity of these infections. 57 There is a definite need for new diagnostic methods and active agents for the diagnosis and treatment of severe fungal infections. 58 Until such progress is made, the optimal approach to these common and severe complications of cancer therapy will probably consist of early administration of the least toxic and optimally effective preparations to those patients known to be at highest risk.
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Out-patient treatment
As already stated, febrile neutropenic patients do not represent a homogenous population and all these patients do not have the same risk of developing serious complications or of death. Moreover, the incidence of rapidly fatal infections, even in patients with severe neutropenia, has markedly decreased over the last few years. Therefore, the standard practice of hospitalizing all febrile neutropenic patients for antibiotic therapy has become an important research issue, particularly in the current health care environment, where cost is being increasingly evaluated.
Following the work of Talcott et al ., 59 which led to the recognition of well-defined risk groups among febrile neutropenic patients, there have been several attempts to treat cancer patients with fever and neutropenia in an outpatient setting. Talcott et al. 60 reported the experience of 30 patients without progressive neoplasia and/or nonneoplastic serious morbidity after early discharge and home treatment with intravenous antibiotics; however, only 16 (53%) responded to the initial regimen (mezlocillin gentamicin or ceftazidime) and nine had to be readmitted for treatment of serious complications or surveillance of persisting fever. Rubenstein et al. 61 selected their febrile neutropenic patients for home therapy on the basis of the lack of any comorbidity requiring hospitalization. They compared an oral regimen (ciprofloxacin clindamycin) with intravenous antibiotics (aztreonam clindamycin); the intravenous regimen was associated with a response of 88%. There is no clear explanation for the difference in response rates in these two pivotal studies, since the selection criteria were quite similar, as were the underlying diseases in both groups; perhaps subtle differences in patient selection and a better coverage of Gram-positive pathogens in the second study might have played a role. It is important to stress that no patient died in either study.
Other strategies included sequential prophylactic antibiotics (rifampicin ciprofloxacin) followed, in the case of fever, by parenteral vancomycin tobramycin once daily and oral ciprofloxacin in patients who had undergone autologous bone marrow transplantation; 62 the incidence of documented infection was greatly reduced and bacteraemias were virtually eliminated; patients could be discharged early to the outpatient setting.
Yet another approach is auto-medication with pefloxacin co-amoxiclav by the patients at home, to be started if fever and/or chills appear; 63 nine failures were seen in 68 patients; two patients presented with a staphylococcal bacteraemia and one of them died. Automedication in febrile neutropenic patients is questionable, because possible signs predicting a poor outcome (sepsis, vasomotor instability, pneumonia) might go undetected and, in addition, microbiological documentation is not feasible. 64 All these observations suggest that many patients with solid tumours and with an expected duration of neutropenia of 7 days, can have their febrile episode managed successfully in an out-patient setting; however, more controlled studies are needed to evaluate the cost-effectiveness and the benefits, in terms of efficacy and quality of life, of this approach.
The use of prophylactic antibiotics and bone marrow growth promoting factors might prove to be more beneficial and cost-effective in low-risk patients allowed home early than in those with more severe and/or protracted neutropenia. The other patients, namely those with haematological malignancies, should probably start therapy for febrile neutropenia as in-patients; however, we need to develop early discharge criteria and home therapeutic strategies for these patients as well. Perhaps sequential strategies such as empirical intravenous antibiotics followed by an early switch to oral medication in responders, as recently reported, 65 might prove not only to be cost-effective but also to improve quality of life in patients with moderately severe neutropenia.
Conclusion
Many problems with empirical therapy of febrile neutropenia remain to be solved; these consist mainly of the increase in the frequency of Gram-positive microorganisms, some of which are methicillin-resistant; the increase in the number of -lactamases in Gram-negative microorganisms; the emergence of new and/or resistant pathogens depending on institutional practices; and the appearance of specific clinical and/or microbiological syndromes according to evolving cancer therapy.
Febrile neutropenia has been a changing syndrome over the last 20 years. The perspectives and goals that we face today are mainly: the constant adaptation of antibacterial prophylactic and therapeutic regimens in response to the emergence of resistant strains; the definition of prognostic factors influencing the outcome of febrile neutropenia; the introduction of pragmatic algorithms for adaptation of therapy; the introduction of ambulatory and/or home therapy for certain categories of patients; the definition of indications for the use of cytokines to restore earlier bone marrow function and to help with home management of febrile neutropenia; and, the recognition of risk factors for fungal infections and the improvement of our diagnostic as well as therapeutic strategies.
